Pharming (PHAR) Enterprise Value (2018 - 2026)
Pharming's (PHAR) quarterly Enterprise Value came in at -$158.3 million in Q2 2026, down 71.87% YoY from -$562.8 million in Q2 2025, and down 202.18% on a QoQ basis from -$52.4 million in Q1 2026.
Pharming (PHAR) Enterprise Value (2018 - 2026) Analysis & Trends
Pharming (PHAR) has 9 years of Enterprise Value data on file, last reported at -$158.3 million in Q2 2026.
- Quarterly Enterprise Value fell 71.87% year-over-year to -$158.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$158.3 million (down 71.87% YoY) and the FY2025 annual result came in at -$145.3 million, down 9587.0% from the prior year.
- Enterprise Value declined to -$158.3 million in Q2 2026, from -$52.4 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$1.5 million in Q4 2024 to a low of -$207.3 million in Q4 2022.
- A 5-year average of -$123.6 million and a median of -$138.8 million in 2025 frame the typical range for Enterprise Value.
- The widest YoY moves for Enterprise Value: up 99.91% in 2022, down 106934.94% in 2022.
- Tracing PHAR's Enterprise Value over 5 years: stood at -$207.3 million in 2022, then surged by 70.22% to -$61.7 million in 2023, then surged by 97.57% to -$1.5 million in 2024, then sank by 9587.0% to -$145.3 million in 2025, then dropped by 8.93% to -$158.3 million in 2026.
- The last three Enterprise Value figures came in at -$158.3 million (Q2 2026), -$52.4 million (Q1 2026), and -$145.3 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Pharming | 824.47 Mn | 666.19 Mn | 141.47 Mn | -158.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -158.28 Mn |
| Mar 31, 2026 | -52.38 Mn |
| Dec 31, 2025 | -145.31 Mn |
| Sep 30, 2025 | -132.37 Mn |
| Jun 30, 2025 | -92.09 Mn |
| Mar 31, 2025 | -58.80 Mn |
| Dec 31, 2024 | -1.50 Mn |
| Sep 30, 2024 | -60.66 Mn |
| Jun 30, 2024 | -47.14 Mn |
| Mar 31, 2024 | -51.89 Mn |
| Dec 31, 2023 | -61.74 Mn |
| Sep 30, 2023 | -207.34 Mn |
| Jun 30, 2023 | -192.37 Mn |
| Mar 31, 2023 | -184.78 Mn |
| Dec 31, 2022 | -207.34 Mn |
| Sep 30, 2022 | -191.92 Mn |
| Jun 30, 2022 | -189.96 Mn |
| Mar 31, 2022 | -189.67 Mn |
| Dec 31, 2021 | -193,714.32 |
| Sep 30, 2021 | -183.32 Mn |